AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33313736
Drug: Self-care CIH
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-care CIH therapies alone (tai chi/qi gong, yoga, meditation)
Trial: 34783204
Drug: HIPEC (hyperthermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC (hyperthermic intraperitoneal chemotherapy) at 42°C (41.5°C‐42.5°C)
Trial: 34783204
Drug: NIPEC (normothermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPEC (normothermic intraperitoneal chemotherapy) at 37°C (36.5°C‐37.5°C)
Trial: 34326185
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (4,000 IU) plus low-dose inhaled fluticasone propionate
Trial: 32434996
Drug: OIL (1.18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OIL (1.18 g/kg, rich in MUFA)
Trial: 35439029
Drug: Navicixizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navicixizumab (3 mg/kg or 4 mg/kg once every 2 weeks) plus Paclitaxel (80 mg/m2 intravenously on days 0, 7, and 14 of 28-day cycles)
Trial: 32095887
Drug: MindMotion™GO exergame
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MindMotion™GO exergame therapy for 30 minutes
Trial: 35075067
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment using a BCI prototype with audio-visual entrainment
Trial: 38652999
Drug: Cenobamate 200
RxNorm normalized name: cenobamate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 200 mg/day
Trial: 35182037
Drug: Cenobamate 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate 500 mg/day
Trial: 34283380
Drug: Daily micro-surveys
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily micro-surveys administered via smartphone application
Trial: 34283380
Drug: Full-length SF-36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-length SF-36 administered preoperatively and at 4, 12, and 24 weeks postoperatively
Trial: 34283380
Drug: Daily micro-surveys
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily micro-surveys
Trial: 34849019
Drug: 40mg chloroprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg chloroprocaine with 5 mcg spinal dexmedetomidine (Spinal Dexgroup)
Trial: 34849019
Drug: 40mg chloroprocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg chloroprocaine with 0.5 mcg/kg IV dexmedetomidine (IV DEXgroup)
Trial: 34564744
Drug: Radiomics signature
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Radiomics signature based on pre-treatment CT scans
Trial: 36494261
Drug: Full-dose S1
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose S1
Trial: 36494261
Drug: Reduced-dose S1
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose S1 + oxaliplatin
Trial: 33127634
Drug: Study definition
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study definition of hyperkalaemia (serum potassium >5.5 mEq/L)
Trial: 33127634
Drug: Study definition
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study definition of hypokalaemia (serum potassium <3.5 mEq/L)
Trial: 33127634
Drug: Higher serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher serum potassium associated with estimated glomerular filtration rate <60 mL/min/1.73 m2
Trial: 33103819
Drug: Ketogenic medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic medium chain triglyceride (kMCT) drink; 15 g twice/day
Trial: 35126621
Drug: Traditional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional oxygen therapy
Trial: 32164382
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of synbiotic treatment with DVB-PVP HD
Trial: 36147581
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (combined formulations containing ethinyl estradiol 10-35 ug/day plus a synthetic progestin) during the active phase of OC use.
Trial: 36147581
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (combined formulations containing ethinyl estradiol 10-35 ug/day plus a synthetic progestin) during the inactive phase of OC use.
Trial: 36147581
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives containing first- or second-generation progestins (the estrane family of progestins or OCs containing levonorgestrel).
Trial: 36147581
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives containing recently developed progestins and lower doses of ethinyl estradiol.
Trial: 36147581
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (various brands classified by estrogenic strength).
Trial: 32643265
Drug: Sub-threshold nano-second
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-threshold nano-second laser (SNL) treatment
Trial: 36205250
Drug: Slurry applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slurry applied immediately to stubble (63,250 L/ha)
Trial: 36205250
Drug: Slurry applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slurry applied after a 1-wk delay (57,484 L/ha)
Trial: 33599975
Drug: Blonanserin transdermal
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin transdermal patch
Trial: 36372315
Drug: TrAsU (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TrAsU (treatment as usual, n = 44)
Trial: 36221341
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (acupuncture and moxibustion)
Trial: 32233095
Drug: Daunorubicin (DNR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin (DNR, 50 mg/m2) with standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation
Trial: 32233095
Drug: Mitoxantrone (MXR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (MXR, 12 mg/m2) with standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation
Trial: 32233095
Drug: Idarubicin (IDA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDA, 10 mg/m2) with standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation
Trial: 34099268
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (30-minute session)
Trial: 32962593
Drug: 0.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg‐1 ketamine (group K1)
Trial: 32962593
Drug: 1 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg.kg‐1 ketamine (group K2)
Trial: 33991085
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for targeted‐therapy related fatigue (CBT‐TTF) delivered via FaceTime for iPad
Trial: 34174128
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose multi-strain probiotic De Simone formulation (112.5 billion viable lyophilized bacteria per capsule) for 3 months
Trial: 33600826
Drug: PACAP38 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PACAP38 infusion (10 pmol/kg/minute)
Trial: 33600826
Drug: PACAP38 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PACAP38 infusion (10 pmol/kg/minute) followed by sumatriptan (4 mg)
Trial: 33600826
Drug: PACAP38 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PACAP38 infusion (10 pmol/kg/minute) followed by placebo (saline)
Trial: 35100758
Drug: Nasal‐oral aspirator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal‐oral aspirator
Trial: 33774765
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care services (PC)
Trial: 34097856
Drug: Therapeutic anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic anticoagulation (in-hospital oral rivaroxaban 20 mg or 15 mg daily for stable patients, or initial subcutaneous enoxaparin 1 mg/kg twice per day or intravenous unfractionated heparin for clinically unstable patients, followed by rivaroxaban to day 30)
Trial: 34097856
Drug: Prophylactic anticoagulation
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anticoagulation (standard in-hospital enoxaparin or unfractionated heparin)
Trial: 36100826
Drug: Ultrasound-guided transversus
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided transversus abdominis plane block (TAPB) with 20 mL 0.5% ropivacaine and patient-controlled intravenous analgesia (PCIA)
Trial: 36100826
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCIA) alone
Trial: 34077237
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with FOLFOX followed by chemoradiation
Trial: 34077237
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with CP followed by chemoradiation
Trial: 34473085
Drug: Detecting and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detecting and validating water molecules and metal ions in maps
Trial: 32211953
Drug: Mild ovarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild ovarian stimulation (MS) using letrozole/antagonist protocol
Trial: 32211953
Drug: Conventional controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional controlled ovarian stimulation (COS) using high dose gonadotropin (Gn) and GnRH-a stop protocol
Trial: 33045287
Drug: Mirabegron (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (25 mg, increased to 50 mg after 4 weeks)
Trial: 35277398
Drug: Myo-inositol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (2 g twice daily until delivery)
Trial: 35277398
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g twice daily until delivery)
Trial: 33813110
Drug: Hydroxychloroquine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (800 mg on day 0 followed by 400 mg per day for 8 days)
Trial: 34549408
Drug: Inhaling essential
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaling essential oil (Lavandula angustifolia 0.1 ml + citrus bergamia 0.1 ml) for 28 days
Trial: 34653425
Drug: Plenvu (1L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plenvu (1L polyethylene glycol-based bowel preparation)
Trial: 34519561
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 40 mg, oral
Trial: 33136231
Drug: Weekly nanoparticle
RxNorm normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly nanoparticle albumin‐bound paclitaxel (nab‐PTX)
Trial: 33136231
Drug: Weekly solvent‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly solvent‐based paclitaxel (Sb‐PTX)
Trial: 34736731
Drug: Rivaroxaban plus
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban plus antiplatelet therapy
Trial: 32062444
Drug: fampridine‐MR 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fampridine‐MR 10 mg bd
Trial: 33478179
Drug: Personalized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized oral health education program in combination with routine dental care
Trial: 33478179
Drug: Personalized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized oral health education program
Trial: 32270639
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (acupuncture at the 'thirteen ghost points' and kaixin powder)
Trial: 32270639
Drug: Chinese medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medication group (kaixin powder only)
Trial: 33485159
Drug: Conventional Class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Class (CC)
Trial: 92313688
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg/24 h for 7 days (Group I)
Trial: 92313688
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg/12 h for 7 days (Group II)
Trial: 35966022
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CrM) supplementation (0.1 g·kg‐1·day‐1)
Trial: 33131908
Drug: 320 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg/day anthocyanins
Trial: 35321886
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride infusion (placebo)
Trial: 33593886
Drug: Neoadjuvant PD-L1
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant PD-L1 inhibition in combination with chemotherapy
Trial: 33900515
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (400 mg every day)
Trial: 32348531
Drug: Intravitreal corticosteroid
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal corticosteroid implants
Trial: 32747361
Drug: Low-dose afabicin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose afabicin (i.v. 80 mg, followed by oral 120 mg, BID)
Trial: 32747361
Drug: High-dose afabicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose afabicin (i.v. 160 mg, followed by oral 240 mg, BID)
Trial: 32747361
Drug: Vancomycin/linezolid (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin/linezolid (i.v. vancomycin 1 g or 15 mg/kg, followed by oral linezolid 600 mg, BID)
Trial: 34444281
Drug: Modified-active release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-active release therapy (mART)
Trial: 32356413
Drug: expedited oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: expedited oral feeding
Trial: 32473365
Drug: Mangifera indica
RxNorm normalized name: MANGIFERA INDICA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mangifera indica leaf extract (MLE), 500 mg orally
Trial: 35643952
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential treatment for H. pylori eradication
Trial: 33226202
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (90 kVp, reduced radiation and standard CM dose)
Trial: 33226202
Drug: Protocol C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol C (90 kVp, standard radiation and reduced CM dose)
Trial: 33670235
Drug: Multidisciplinary Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary Assessment and Treatment including ACT (TEAM)
Trial: 33670235
Drug: Control (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Treatment as Usual)
Trial: 36432436
Drug: Nutraceutical group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical group (MHD plus nutraceutical supplementation: Vitamin E, L-glutathione, silymarin, and hepato-active compounds)
Trial: 34817396
Drug: Midazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2 mg intravenously)
Trial: 36284288
Drug: Glycopyrrolate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.2 mg IV)
Trial: 33765358
Drug: PF-06410293 (adalimumab-afzb)
RxNorm normalized name: adalimumab-afzb
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-06410293 (adalimumab-afzb) administered by prefilled syringe (PFS)
Trial: 33765358
Drug: PF-06410293 (adalimumab-afzb)
RxNorm normalized name: adalimumab-afzb
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-06410293 (adalimumab-afzb) administered by prefilled pen (PFP)
Trial: 35965182
Drug: 2-mA anodal
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mA anodal 20-minute tDCS over the left primary motor cortex, administered three consecutive sessions every month for five months
Trial: 35028171
Drug: Comfrey ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comfrey ointment
Trial: 35180097
Drug: Oral Aceclofenac
RxNorm normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Aceclofenac sustained-release tablets, calcium carbonate and vitamin D3 tablets
Trial: 32040183
Drug: List experiment
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: List experiment method (treatment group)
Trial: 32682507
Drug: Heated fennel
RxNorm normalized name: Fennel
DrugBank: Fennel (DB15615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated fennel therapy
Trial: 36397122
Drug: 12 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 sessions of concurrent PCC ISF up‐training and dorsal anterior cingulate cortex (dACC) ISF‐NFB down‐training (n=15)
Trial: 33498640
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium meal plan (0.9 mg/kcal)
Trial: 33498640
Drug: Typical sodium
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical sodium meal plan (2 mg/kcal)
Trial: 32285223
Drug: AT13148 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AT13148 treatment in BT474 and PC3 cells
Trial: 32285223
Drug: AT13148 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AT13148 treatment in non-tumor bearing mice
Trial: 32285223
Drug: AT13148 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AT13148 treatment in patients at doses of 160-300 mg
Trial: 34444656
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg/kg of body mass)
Trial: 36201455
Drug: 100 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g/day of fermented vegetables (group A)
Trial: 36201455
Drug: 100 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g/day pickled vegetables (group B)
Trial: 34189135
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion during general anesthesia
Trial: 32756643
Drug: Probiotic therapy
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic therapy (Lactobacillus para casei LPC‐37, Lactobacillus rhamnosus HN001, Lactobacillus acidophilus NCFM, Bifidobacterium lactis HN019, 109 CFU of each strain) for 8 weeks
Trial: 32756643
Drug: Placebo (polydextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (polydextrose 1 g day‐1 for 8 weeks)
Trial: 36001989
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg BID with aspirin 100 mg
Trial: 35830143
Drug: Neutral fluoride
RxNorm normalized name: SODIUM FLUORIDE 0.9 mg in 1 g DENTAL AEROSOL, FOAM [KOLORZ NEUTRAL FLUORIDE FOAM TRIPLE MINT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral fluoride gel (NFG)
Trial: 36075594
Drug: Scraping needling
RxNorm normalized name: Sarapin
DrugBank: Sarracenia Purpurea (DB13965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scraping needling technique combined with western medication
Trial: 36075594
Drug: Simple western
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple western medication (control group)